University of Minnesota
MICaB Graduate Program
http://micab.umn.edu
MICaB Home | U of M Medical School | Graduate School

Unit's home page.

MICaB Faculty

Stromnes
Ingunn Stromnes, Ph.D.

Assistant Professor

Department of Microbiology and Immunology

University of Washington, 2007, Ph.D.

612-626-7771 office

E-mail:ingunn@umn.edu


Research Interests:

Cancer immunology and immunothereapy; T cell engineering

The Stromnes laboratory is focused on advancing the understanding of cancer immunology and immunotherapy, with a particular emphasis on properties of the tumor and the tumor microenvironment that influence antigen-specific T lymphocyte migration and function. The laboratory aims to uncover how tumors and their mutations coordinate a suppressive microenvironment and elicit a program of T cell dysfunction. The lab is also focused on understanding the cellular and acellular components of tumor microenvironment that influence immunotherapy response. The laboratory combines studies of human tumors, genetically engineered mouse models that faithfully recapitulate human cancer, and novel cell engineering approaches evaluated in both mouse and human T cells to develop next generation cellular therapies for intractable malignancies, with a major focus on carcinomas including pancreatic cancer. Preclinical studies performed by Dr. Stromnes and colleagues have led to a novel engineered T cell therapy for pancreatic and ovarian cancer patient treatment.

Selected Recent Publications:

  • Stromnes, I.M., Hulbert, A., Pierce, R., Greenberg P.D. and Hingorani SR. (2017) T cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunology Research, In Press.
  • Anderson KG, Stromnes IM, Greenberg PD. (2017). Obstacles posed by the tumor microenvironment: a case for synergistic therapies. Cancer Cell. 31 (3):311-325.
  • Stromnes IM, Greenberg PD. Pancreatic cancer: Planning ahead for metastatic spread. Cancer Cell. (2016) 13;29(6):774-6.
  • Stromnes, I.M., Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR. (2015) Engineered T cells against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell. 28(5):638-652.
  • Schmitt, T., Stromnes, I.M., Chapuis, A. and Greenberg, P.D. (2015) New strategies in engineering T-cell receptor gene-modified T cells to more effectively target malignancies. Clin Canc Res 21(23):5191-7.
  • Stromnes, I.M., Greenberg, PD., and Hingorani, S.R. (2014) Molecular pathways: myeloid complicity in cancer. Clinical Cancer Research 20 (20): 5157-70.
  • Stromnes, I.M., Delgiornio, K.E., Greenberg, P.D., and Hingorani, S.R. (2014) Stromal re-engineering to treat pancreas cancer. Carcinogenesis 35 (7): 1451-60.
  • Stromnes, I.M., Brockenbrough, S., Kamel Izeradjene, K., Carlson, M.A., Cuevas, C., Simmons, R.M., Greenberg, P.D., and Hingorani, S.R. (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63 (11): 1769-1781.
  • Stromnes, I.M., Schmitt, T., Chapuis, A., Hingorani, S.R., and Greenberg, P.D. (2014) Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews 257 (1): 145-64.
  • Pierson, E.R., Stromnes, I.M., Goverman, J. (2014) B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system. Journal of Immunology 192 (3): 929-939.
  • Schmitt, T.M., Aggen, D.H., Stromnes, I.M., Dosset, M., Kranz, D.M., and Greenberg, P.D. (2013) Enhanced-affinity TCRs specific for tumor-associated self-antigens and expressed in peripheral T cells can be safe for TCR gene therapy despite surpassing the affinity threshold for normal thymic selection. Blood 122 (3): 348-356.
  • Stromnes, I.M., Fowler, C., Casamina, C.C., Georgopolos, C.M., McAfee, M.S., Schmitt, T.M., Tan. X., Kim, T.D., Choi, I., Blattman, J.B., Greenberg, P.D. (2012) Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. Journal of Immunology 189: 1812-1825.
  • Johnson, P.L., Kochin, B.F., McAfee, M.S., Stromnes, I.M., Regoes, R.R., Ahmed, R., Blattman, J.N., and Antia, R. (2011) Vaccination alters the balance between protective immunity, exhaustion, escape and death in chronic infections. Journal of Virology 85: 5565-70.
  • Stromnes, I.M., Blattman, J.N., Tan, X., Jeevanjee, S., Gu, H., and Greenberg, P.D. (2010) Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice. Journal of Clinical Investigation 120: 3722-3734.
  • Stromnes, I.M., Cerretti, L.M., Liggitt, D., Harris, R.A., and Goverman, J.M. (2008) Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nature Medicine 14: 337-342.
  • Stromnes, I.M., and Goverman, J.M. (2007) Osteopontin-induced survival of T cells. Nature Immunology 8, 19-20.